Post-treatment Effect of Galcanezumab in Migraine Post-treatment Effect of Galcanezumab in Migraine

Does galcanezumab, which has a long half-life of 27 days, demonstrate persistence of response or of adverse events after migraine treatment cessation?Headache

Source: Medscape Today Headlines - June 25, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news